Assessing the utility of confirmatory studies following identification of large-scale genomic imbalances by microarray

Jennifer N Sanmann, Diane L. Pickering, Denae M. Golden, Jadd M. Stevens, Thomas E. Hempel, Pamela A. Althof, Michele L. Wiggins, Lois J Starr, Bhavana J Dave, Warren G. Sanger

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The identification of clinically relevant genomic dosage anomalies assists in accurate diagnosis, prognosis, and medical management of affected individuals. Technological advancements within the field, such as the advent of microarray, have markedly increased the resolution of detection; however, clinical laboratories have maintained conventional techniques for confirmation of genomic imbalances identified by microarray to ensure diagnostic accuracy. In recent years the utility of this confirmatory testing of large-scale aberrations has been questioned but has not been scientifically addressed. Methods: We retrospectively reviewed 519 laboratory cases with genomic imbalances meeting reportable criteria by microarray and subsequently confirmed with a second technology, primarily fluorescence in situ hybridization. Results: All genomic imbalances meeting reportable criteria detected by microarray were confirmed with a second technology. Microarray analysis generated no false-positive results. Conclusion: Confirmatory testing of large-scale genomic imbalances (deletion of ≥150 kb, duplication of ≥ 500 kb) solely for the purpose of microarray verification may be unwarranted. In some cases, however, adjunct testing is necessary to overcome limitations inherent to microarray. A recommended clinical strategy for adjunct testing following identified genomic imbalances using microarray is detailed.

Original languageEnglish (US)
Pages (from-to)875-879
Number of pages5
JournalGenetics in Medicine
Volume17
Issue number11
DOIs
StatePublished - Nov 1 2015

Fingerprint

Technology
Microarray Analysis
Fluorescence In Situ Hybridization

Keywords

  • Confirmatory testing
  • copy-number variation
  • fluorescence in situ hybridization
  • genomic imbalances
  • microarray

ASJC Scopus subject areas

  • Genetics(clinical)

Cite this

Sanmann, J. N., Pickering, D. L., Golden, D. M., Stevens, J. M., Hempel, T. E., Althof, P. A., ... Sanger, W. G. (2015). Assessing the utility of confirmatory studies following identification of large-scale genomic imbalances by microarray. Genetics in Medicine, 17(11), 875-879. https://doi.org/10.1038/gim.2014.204

Assessing the utility of confirmatory studies following identification of large-scale genomic imbalances by microarray. / Sanmann, Jennifer N; Pickering, Diane L.; Golden, Denae M.; Stevens, Jadd M.; Hempel, Thomas E.; Althof, Pamela A.; Wiggins, Michele L.; Starr, Lois J; Dave, Bhavana J; Sanger, Warren G.

In: Genetics in Medicine, Vol. 17, No. 11, 01.11.2015, p. 875-879.

Research output: Contribution to journalArticle

Sanmann, Jennifer N ; Pickering, Diane L. ; Golden, Denae M. ; Stevens, Jadd M. ; Hempel, Thomas E. ; Althof, Pamela A. ; Wiggins, Michele L. ; Starr, Lois J ; Dave, Bhavana J ; Sanger, Warren G. / Assessing the utility of confirmatory studies following identification of large-scale genomic imbalances by microarray. In: Genetics in Medicine. 2015 ; Vol. 17, No. 11. pp. 875-879.
@article{95ce24eef40f4388aa104831e99bcb1d,
title = "Assessing the utility of confirmatory studies following identification of large-scale genomic imbalances by microarray",
abstract = "The identification of clinically relevant genomic dosage anomalies assists in accurate diagnosis, prognosis, and medical management of affected individuals. Technological advancements within the field, such as the advent of microarray, have markedly increased the resolution of detection; however, clinical laboratories have maintained conventional techniques for confirmation of genomic imbalances identified by microarray to ensure diagnostic accuracy. In recent years the utility of this confirmatory testing of large-scale aberrations has been questioned but has not been scientifically addressed. Methods: We retrospectively reviewed 519 laboratory cases with genomic imbalances meeting reportable criteria by microarray and subsequently confirmed with a second technology, primarily fluorescence in situ hybridization. Results: All genomic imbalances meeting reportable criteria detected by microarray were confirmed with a second technology. Microarray analysis generated no false-positive results. Conclusion: Confirmatory testing of large-scale genomic imbalances (deletion of ≥150 kb, duplication of ≥ 500 kb) solely for the purpose of microarray verification may be unwarranted. In some cases, however, adjunct testing is necessary to overcome limitations inherent to microarray. A recommended clinical strategy for adjunct testing following identified genomic imbalances using microarray is detailed.",
keywords = "Confirmatory testing, copy-number variation, fluorescence in situ hybridization, genomic imbalances, microarray",
author = "Sanmann, {Jennifer N} and Pickering, {Diane L.} and Golden, {Denae M.} and Stevens, {Jadd M.} and Hempel, {Thomas E.} and Althof, {Pamela A.} and Wiggins, {Michele L.} and Starr, {Lois J} and Dave, {Bhavana J} and Sanger, {Warren G.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1038/gim.2014.204",
language = "English (US)",
volume = "17",
pages = "875--879",
journal = "Genetics in Medicine",
issn = "1098-3600",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - Assessing the utility of confirmatory studies following identification of large-scale genomic imbalances by microarray

AU - Sanmann, Jennifer N

AU - Pickering, Diane L.

AU - Golden, Denae M.

AU - Stevens, Jadd M.

AU - Hempel, Thomas E.

AU - Althof, Pamela A.

AU - Wiggins, Michele L.

AU - Starr, Lois J

AU - Dave, Bhavana J

AU - Sanger, Warren G.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - The identification of clinically relevant genomic dosage anomalies assists in accurate diagnosis, prognosis, and medical management of affected individuals. Technological advancements within the field, such as the advent of microarray, have markedly increased the resolution of detection; however, clinical laboratories have maintained conventional techniques for confirmation of genomic imbalances identified by microarray to ensure diagnostic accuracy. In recent years the utility of this confirmatory testing of large-scale aberrations has been questioned but has not been scientifically addressed. Methods: We retrospectively reviewed 519 laboratory cases with genomic imbalances meeting reportable criteria by microarray and subsequently confirmed with a second technology, primarily fluorescence in situ hybridization. Results: All genomic imbalances meeting reportable criteria detected by microarray were confirmed with a second technology. Microarray analysis generated no false-positive results. Conclusion: Confirmatory testing of large-scale genomic imbalances (deletion of ≥150 kb, duplication of ≥ 500 kb) solely for the purpose of microarray verification may be unwarranted. In some cases, however, adjunct testing is necessary to overcome limitations inherent to microarray. A recommended clinical strategy for adjunct testing following identified genomic imbalances using microarray is detailed.

AB - The identification of clinically relevant genomic dosage anomalies assists in accurate diagnosis, prognosis, and medical management of affected individuals. Technological advancements within the field, such as the advent of microarray, have markedly increased the resolution of detection; however, clinical laboratories have maintained conventional techniques for confirmation of genomic imbalances identified by microarray to ensure diagnostic accuracy. In recent years the utility of this confirmatory testing of large-scale aberrations has been questioned but has not been scientifically addressed. Methods: We retrospectively reviewed 519 laboratory cases with genomic imbalances meeting reportable criteria by microarray and subsequently confirmed with a second technology, primarily fluorescence in situ hybridization. Results: All genomic imbalances meeting reportable criteria detected by microarray were confirmed with a second technology. Microarray analysis generated no false-positive results. Conclusion: Confirmatory testing of large-scale genomic imbalances (deletion of ≥150 kb, duplication of ≥ 500 kb) solely for the purpose of microarray verification may be unwarranted. In some cases, however, adjunct testing is necessary to overcome limitations inherent to microarray. A recommended clinical strategy for adjunct testing following identified genomic imbalances using microarray is detailed.

KW - Confirmatory testing

KW - copy-number variation

KW - fluorescence in situ hybridization

KW - genomic imbalances

KW - microarray

UR - http://www.scopus.com/inward/record.url?scp=84947922005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947922005&partnerID=8YFLogxK

U2 - 10.1038/gim.2014.204

DO - 10.1038/gim.2014.204

M3 - Article

C2 - 25590977

AN - SCOPUS:84947922005

VL - 17

SP - 875

EP - 879

JO - Genetics in Medicine

JF - Genetics in Medicine

SN - 1098-3600

IS - 11

ER -